Mesothelioma trends in the ACT and comparisons with the rest of Australia

Korda, Rosemary; Clements, Mark; Armstrong, Bruce K.; Trevenar, Susan; Chalker, Elizabeth; Newman, Leah A.; Kirk, Martyn

doi:10.17061/phrp2641646

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trends in age-adjusted rates are consistent with those reported in recent years for individual countries on the basis of either mortality or incidence data, for example, Australia, 9 Germany, 10 the United States, 6 and England. 11 An analysis of temporal trends in age-specific rates, however, was reported only for 1998 to 2002 in southeast England 12 ; its results were similar to ours, although on the basis of small numbers.…”

supporting

confidence: 85%

International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

Boffetta

Malvezzi

Pira

et al. 2018

JGO

View full text Add to dashboard Cite

Past analyses of mortality data from mesothelioma relied on unspecific codes, such as pleural neoplasms. We calculated temporal trends in age-specific mortality rates in Canada, the United States, Japan, France, Germany, Italy, the Netherlands, Poland, the United Kingdom, and Australia on the basis of the 10th version of the International Classification of Diseases, which includes a specific code for mesothelioma. Older age groups showed an increase (in the United States, a weaker decrease) during the study period, whereas in young age groups, there was a decrease (in Poland, a weaker increase, starting, however, from low rates). Results were consistent between men and women and between pleural and peritoneal mesothelioma, although a smaller number of events in women and for peritoneal mesothelioma resulted in less precise results. The results show the heterogeneous effect of the reduction of asbestos exposure on different age groups; decreasing mortality in young people reflects reduced exposure opportunity, and increasing mortality in the elderly shows the long-term effect of early exposures.

show abstract

supporting

confidence: 85%

International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

Boffetta

Malvezzi

Pira

et al. 2018

JGO

View full text Add to dashboard Cite

show abstract

“…Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a very strong association with asbestos exposure . MPM accounts for fewer than 1% of all malignancies and has a reported median survival of 7 months, which has remained unchanged during the last four decades …”

Section: Introductionmentioning

confidence: 99%

“…1 MPM accounts for fewer than 1% of all malignancies and has a reported median survival of 7 months, which has remained unchanged during the last four decades. 2 Reported predictors of longer survival include female sex, younger age at diagnosis, localised disease and epithelioid morphology. 3,4 Recently, mutation or inactivation of BAP1, a tumour suppressor gene which encodes a nuclear ubiquitin carboxyterminal hydrolase, have been reported to be a key driver event in 15-79% of MPM.…”

Section: Introductionmentioning

confidence: 99%

The epithelioid BAP1‐negative and p16‐positive phenotype predicts prolonged survival in pleural mesothelioma

et al. 2017

View full text Add to dashboard Cite

show abstract

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Opitz

Scherpereel

Berghmans

et al. 2020

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pretherapeutic assessment. Monitoring: patient’s performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasize that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

show abstract

Mesothelioma trends in the ACT and comparisons with the rest of Australia

Cited by 4 publications

References 5 publications

International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

The epithelioid BAP1‐negative and p16‐positive phenotype predicts prolonged survival in pleural mesothelioma

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Contact Info

Product

Resources

About